Stockwatch: Riding the M&A rollercoaster
This article was originally published in Scrip
An important dynamic currently driving the biopharmaceutical space is the replacement of lost product revenue at pharmaceutical companies through merger and acquisition (M&A) transactions biotechs with promising pipelines. However, the hoped for renewal is not always a smooth path and is more often more akin to riding a rollercoaster.
You may also be interested in...
After a slow start marked by product withdrawals and toxicity, recent deal-making activity has brought antibody-drug conjugates back from obscurity. But what has changed?
The pandemic has affected generic pharmaceutical companies more than their branded brethren but accident-prone Mallinckrodt has been hit harder than most.
Apparently positive news for two unglamorous indications – acne and allergy – should be balanced against restrictive reimbursement and market fragmentation.